ReviewCurrent opinion in pharmacology2011
A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.
Review in Current opinion in pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between HIV and acquisition of rifamycin resistance with first-line TB treatment: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease.The Journal of antimicrobial chemotherapy · 2026Article
- Acute Plasmodium yoelii 17XNL Infection During BCG Vaccination Limits T Cell Responses and Mycobacterial Growth Inhibition.Immunology · 2025Article
- Development of a Multiplex Real-Time PCR for Diagnosis of Tuberculosis and Multidrug Resistance.Current microbiology · 2025Article
- Examining effective monotherapy hypothesis for TB therapy failure and resistance emergence.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2024Article
- Machine Learning Approach in Dosage Individualization of Isoniazid for Tuberculosis.Clinical pharmacokinetics · 2024Article
- Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistantAntimicrobial agents and chemotherapy · 2024Article
- Spatiotemporal perspectives on tuberculosis chemotherapy.Current opinion in microbiology · 2023Review
- HowFrontiers in cellular and infection microbiology · 2022Review
- Antibacterial pathway of cefquinome against Staphylococcus aureus based on label-free quantitative proteomics analysis.Journal of microbiology (Seoul, Korea) · 2021Article
- Rifampicin exposure reveals within-host Mycobacterium tuberculosis diversity in patients with delayed culture conversion.PLoS pathogens · 2021Article
- Machine learning reveals that Mycobacterium tuberculosis genotypes and anatomic disease site impacts drug resistance and disease transmission among patients with proven extra-pulmonary tuberculosis.BMC infectious diseases · 2020Article
- Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase fromInfection and drug resistance · 2020Article
- The effect of anti-tuberculosis drugs therapy on mRNA efflux pump gene expression ofNew microbes and new infections · 2019Article
- Does oxidative stress contribute to antituberculosis drug resistance?Journal of thoracic disease · 2019Article
- Article
- Amoxicillin Administration Regimen and Resistance Mechanisms ofFrontiers in microbiology · 2019Article
- Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
- Insights into the processes that drive the evolution of drug resistance inEvolutionary applications · 2018Review
- Use of classification and regression tree (CART), to identify hemoglobin A1C (HbAJournal of clinical tuberculosis and other mycobacterial diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The current understanding of the mechanism of anti-tuberculosis drug resistance has been shaped by the history of development of anti-tuberculosis drugs in the past 60 years and was arrived at as part of inductive generalization. Recently, these standard beliefs have been tested in controlled hollow fiber systems experiments. Drug resistance in Mycobacterium tuberculosis was shown to be related to pharmacokinetic-pharmacodynamic (PK/PD) factors, and factors such as pharmacokinetic variability. Poor PK/PD exposures owing to our current non-optimized dosing regimens initiate a chain of evolution driven events, starting with induction of multi-drug efflux pumps, followed by the development of chromosomal mutations in time, which together lead to high level resistance multi-drug resistant tuberculosis and extremely drug resistant tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.